How We Got Here: Baxalta And Shire Reach Final Merger Hurdle
This article was originally published in Scrip
Executive Summary
Following Baxalta Inc.'s announcement that it will hold a special meeting of stockholders on May 27 for investors to cast the final vote on its merger agreement with specialty biopharma company Shire, Scrip has taken a look back over the last year to see how this $32bn deal got made.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.